Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans‐Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer - Denham, James W.; Nowitz, Michael; Joseph, David; Duchesne, Gillian; Spry, Nigel A.; Lamb, David S.; Matthews, John; Turner, Sandra; Atkinson, Chris; Tai, Keen‐Hun; Gogna, Nirdosh Kumar; Kenny, Lizbeth; et al. (BJU international, 2014)
Keywords: Aged; Aged, 80 and over; Androgen Antagonists - administration & dosage; Androgen Antagonists - adverse effects; androgen suppression; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - adverse effects; Australia; Biological and medical sciences; bisphophonate; Bone Density - drug effects; Bone Density Conservation Agents - therapeutic use; bone mineral density; Diphosphonates - therapeutic use; Follow-Up Studies; fractures; Humans; Imidazoles - therapeutic use; Male; Medical sciences; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Nephrology. Urinary tract diseases; New Zealand; prostate cancer; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Spinal Fractures - chemically induced; Spinal Fractures - prevention & control; Treatment Outcome; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; New Zealand; Australia; Nephrology; Antiosteoporotic; Prostate disease; bisphophonate; Suppression; Diseases of the osteoarticular system; Antiresorptive agent; Diphosphonic acid derivatives; Fracture; Bisphosphonates; Urology; Randomization; androgen suppression; Cancerology; Antiosteoclastic agent; Androgen deprivation; Zoledronic acid; Male genital diseases; fractures; Urinary system disease; Androgen deprivation therapy; Androgen; Malignant tumor; Radiotherapy; Trauma; Randomized controlled trial; Bone mineral density; Locally advanced stage; Sex steroid hormone; Prostate cancer; Cancer; bone mineral density; prostate cancer